Bildkälla: Stockfoto

InDex Pharmaceuticals Q3 2023: Uncertain future post discontinuation of CONCLUDE - Redeye

Redeye sees a new investment case in InDex Pharmaceuticals following the discontinuation of CONCLUDE. The share trades at a substantial discount compared to its book value, which offers an interesting play on the company’s future trajectory.

Redeye sees a new investment case in InDex Pharmaceuticals following the discontinuation of CONCLUDE. The share trades at a substantial discount compared to its book value, which offers an interesting play on the company’s future trajectory.
Börsvärldens nyhetsbrev
ANNONSER